Cancer Treatment Centers of America: Clinical Trials
Learn More About This Topic: Chat with Us | Email Us
A Phase I/II Study of the Safety and Biological Activity of Intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI- Cholesterol lipopolymer) Administered alone and in Combination with Standard Chemotherapy in Colorectal Peritoneal Carcinomatosis Patients who had Previously Received Cytoreductive Surgery plus HIPEC Therapy.
This study is for patients with Colorectal cancer and peritoneal (abdominal) metastases who require cytoreductive surgery.The study will assess the effect of EGEN-001 administered into the abdomen.
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.